LONDON, August 28, 2025 — Leads & Copy — Leucid Bio will attend the Morgan Stanley 23rd Annual Global Healthcare Conference in New York, the privately-held biotechnology company announced. CEO Filippo Petti will participate in a fireside chat at 1:05 p.m. ET on Monday, September 8, 2025. Company management will also participate in one-on-one meetings at the conference.
Leucid Bio develops cell therapies for the treatment of solid tumors using its proprietary lateral CAR platform. The Company’s lead asset, LEU011, is an autologous CAR-T cell therapy targeting NKG2D ligands, which are expressed on more than 80% of human tumours. In addition, LEU011 co-expresses the chemokine receptor CXCR2 which is engineered to enhance cell trafficking and tumour infiltration.
Filippo Petti, Chief Executive Officer
